Education
About Us
Working with TipRanks
Follow Us
Cutia Therapeutics (HK:2487)
:2487
2487 Stock Chart & Stats
HK$4.59
-HK$0.09(-1.60%)
At close: 4:00 PM EST
HK$4.59
-HK$0.09(-1.60%)
Day’s Range― - ―
52-Week RangeHK$3.64 - HK$12.84
Previous CloseN/A
Volume1.53M
Average Volume (3M)399.60K
Market Cap
HK$1.86B
Enterprise ValueHK$1.60B
Total Cash (Recent Filing)HK$681.51M
Total Debt (Recent Filing)HK$290.40M
Price to Earnings (P/E)―
Beta1.03
Next Earnings
Mar 31, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.83
Shares Outstanding364,730,870
10 Day Avg. Volume272,590
30 Day Avg. Volume399,603
Financial Highlights & Ratios
PEG Ratio0.06
Price to Book (P/B)2.00
Price to Sales (P/S)6.98
P/FCF Ratio-4.16
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Revenue GrowthSustained revenue growth near 26% demonstrates improving commercial traction and product uptake. Over a 2–6 month horizon this supports reinvestment in R&D and operations, reduces execution risk, and increases the odds management can scale toward durable profitability if growth persists.
Balance Sheet ImprovementRecovery to positive stockholders' equity and relatively low leverage materially improves solvency and financial flexibility. This durable improvement reduces bankruptcy risk, enhances ability to fund trials or commercialization, and supports multi-quarter planning versus peers with weak equity.
Orphan/ Specialized FocusConcentrating on rare and complex diseases creates structural advantages—regulatory incentives, pricing power, and smaller targeted populations—which can produce higher margin, more defensible franchises over time. This business model supports durable revenue per approved product.
Bears Say
Negative Cash FlowPersistent negative operating and free cash flow constrains internal funding for trials and commercialization, forcing ongoing reliance on external capital. Over several months this raises dilution or interest costs, limits strategic optionality, and can delay development milestones if financing is tight.
Sustained Losses And Weak MarginsDespite revenue gains, continued negative net income and EBIT margins reflect high operating and R&D spend that erode profitability. Without structural margin improvement or scalable cost control, losses may persist and necessitate external funding, constraining long-term capital allocation and growth.
Equity VolatilityA history of fluctuating equity—though recently recovered—signals instability in the capital structure. Recurring swings can weaken borrowing capacity, deter partnership or licensing negotiations, and complicate multi-quarter planning as management balances financing needs against dilution and credibility concerns.
Cutia Therapeutics News
2487 FAQ
What was Cutia Therapeutics’s price range in the past 12 months?
Cutia Therapeutics lowest stock price was HK$3.64 and its highest was HK$12.84 in the past 12 months.
What is Cutia Therapeutics’s market cap?
Cutia Therapeutics’s market cap is HK$1.86B.
When is Cutia Therapeutics’s upcoming earnings report date?
Cutia Therapeutics’s upcoming earnings report date is Mar 31, 2026 which is in 34 days.
How were Cutia Therapeutics’s earnings last quarter?
Cutia Therapeutics released its earnings results on Aug 28, 2025. The company reported -HK$0.826 earnings per share for the quarter, missing the consensus estimate of N/A by -HK$0.826.
Is Cutia Therapeutics overvalued?
According to Wall Street analysts Cutia Therapeutics’s price is currently Overvalued.
Does Cutia Therapeutics pay dividends?
Cutia Therapeutics does not currently pay dividends.
What is Cutia Therapeutics’s EPS estimate?
Cutia Therapeutics’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Cutia Therapeutics have?
Cutia Therapeutics has 364,730,870 shares outstanding.
What happened to Cutia Therapeutics’s price movement after its last earnings report?
Cutia Therapeutics reported an EPS of -HK$0.826 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went down -0.934%.
Which hedge fund is a major shareholder of Cutia Therapeutics?
Currently, no hedge funds are holding shares in HK:2487
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Cutia Therapeutics Stock Smart Score
Underperform
1
2
3
4
5
6
7
8
9
10
Technicals
SMA
Negative
20 days / 200 days
Momentum
-24.34%
12-Months-Change
Fundamentals
Return on Equity
-48.42%
Trailing 12-Months
Asset Growth
-24.52%
Trailing 12-Months
Company Description
Cutia Therapeutics
Cutia Therapeutics operates as a biopharmaceutical company that develops a dermatology platform for skin and scalp diseases. The company focuses on the dermatology treatment and care therapeutic areas, including localized adipose accumulation management medication, scalp diseases and care, skin diseases and care, and topical anesthesia. The company was incorporated in 2019 and is based in Shanghai, China with additional offices in Beijing, Wuxi and Hong Kong.
Technical Analysis
Jacobio Pharmaceuticals Group Co., Ltd.
―
Viva Biotech Holdings
―
Jiangsu Recbio Technology Co., Ltd. Class H
―
CStone Pharmaceuticals
―
SinoMab Bioscience Ltd.
―